Site-Specific, Stoichiometric-Controlled, PEGylated Conjugates of Fibroblast Growth Factor 2 (FGF2) with Hydrophilic Auristatin Y for Highly Selective Killing of Cancer Cells Overproducing Fibroblast Growth Factor Receptor 1 (FGFR1)

[Image: see text] In spite of significant progress in the field of targeted anticancer therapy, the FDA has approved only five ADC-based drugs. Hence the search for new targeted anticancer agents is an unfulfilled necessity. Here, we present novel types of protein–drug conjugates (PDCs) that exhibit...

Descripción completa

Detalles Bibliográficos
Autores principales: Krzyscik, Mateusz Adam, Zakrzewska, Małgorzata, Otlewski, Jacek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2020
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7588128/
https://www.ncbi.nlm.nih.gov/pubmed/32501706
http://dx.doi.org/10.1021/acs.molpharmaceut.0c00419

Ejemplares similares

Ejemplares similares